Top Companies in Exosome Diagnostics and Therapeutics Market

The exosome diagnostics market is projected to grow from USD 59 million in 2024 to USD 2,347 million by 2029 at a CAGR of 108.9%. However, the candidates for exosome-based therapeutics are expected to be launched in the market from 2029 onwards. Thus, collectively exosome diagnostics and therapeutics market is expected to generate USD 59 million by 2024 and projected to reach USD 6,848 million in 2032 at a CAGR of 81.2%. As of 2024, Bio-Techne (US) monopolizes the exosome diagnostics market as the only company with approved and commercialized exosome-based test.

The players mapped in the report include Bio-Techne (US), NanoFCM Inc. (UK), System Biosciences, LLC. (US), Capital Biosciences, Inc. (US), AMSBIO (UK), INOVIQ (Australia), Direct Biologics LLC (US), Regeneus Ltd (Australia), CUREXSYS (Germany), Aegle Therapeutics (US), Mercy Bioanalytics (US), multimmune GmbH (Germany), RION (US), Exogenus Therapeutics (Portugal), Everzom (France), Kimera Labs (US) NanoSomiX, Inc. (US), Exonox Biosciences, Inc. (Taiwan), Capricor Therapeutics, Inc. (US), Evox Therapeutics (US), and ILIAS Biologics Inc. (Korea). The global exosome diagnostics and therapeutics market is a monopolized market, some of the market players are anticipated to lead the market, which include Bio-Techne (US), NanoFCM Inc. (UK), System Biosciences, LLC. (US), Capital Biosciences, Inc. (US), AMSBIO (UK), INOVIQ (Australia), Direct Biologics LLC (US), Regeneus Ltd (Australia), CUREXSYS (Germany), and Aegle Therapeutics (US).

To know about the assumptions considered for the study download the pdf brochure

Bio-Techne (US) is the leading prominent market player in the exosome diagnostics market; the firm's dominance is expected to continue in the coming years. The global exosome diagnostics and therapeutics market is nascent, with commercial products approved only in the diagnostics market space. This has created a monopoly in the market, with Bio-Techne (US) being the only player currently offering commercial exosome-based tests. The ExoDx prostate cancer test is a key product offered by Bio-Techne.

Bio-Techne entered the exosome market by acquiring Exosome Diagnostics Inc. in 2018. This strategic acquisition helped expand Bio-Techne’s market presence for liquid biopsy diagnostics. Since the acquisition, Bio-Techne has released the ExoDx Prostate (EPI) Test, the firm’s flagship diagnostic product. ExoDx is a non-invasive liquid biopsy test for risk assessment of prostate cancer.

Other players include companies that offer isolation kits, preparation kits, and liquid biopsy kits designed for applications apart from research use only (RUO). Other players representing a very less revenue share of the market include NanoFCM Inc. (UK), System Biosciences, LLC. (US), Capital Biosciences, Inc. (US), AMSBIO (UK), and INOVIQ (Australia). Of these Capital Biosciences, Inc. (US), AMSBIO (UK), and INOVIQ (Australia) are expected to emerge as strong players in the market.

AMSBIO (UK) is a leading provider of life science research reagents & services for R&D, especially in genomics, proteomics, cell culture, and stem cell sciences. The company offers exosome isolation tools such as reagents, immunobeads, and immunoplates for overall or specific intact exosome isolation from small volumes of biological fluids or cell media samples. Whereas, INOVIQ (Australia) is commercializing advanced precision diagnostics and exosome solutions that improve cancer treatment & diagnosis. INOVIQ operates in one reportable segment and generates revenue through two commercial products: EXO-NET and hTERT test. EXO-NET is a pan-exosome capture tool suitable for research applications, whereas the hTERT test is used as an adjunct to urine cytology testing for bladder cancer.

Related Reports:

Exosome Diagnostics and Therapeutics Market by Type (Diagnostics, Therapeutics), Product & Service (Instruments, Kits, Reagents), Source (Stem Cells, Blood, Blood Plasma, Urine), Application (Cancer, Musculoskeletal, CVD) - Global Forecast to 2032

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com